Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted ...
UK biotech Engitix has raised a $25 million series A extension from existing investor Netherton Investments, investing on behalf of BlueCrest Capital Management co-founder Mike Platt. The funding will ...
Hundreds of genes have been linked to autism, but knowing which ones matter most has been a challenge. Researchers at the University of Aberdeen combined data from thousands of developing human brain ...
StimLabs®, a leading regenerative medicine company, announces the launch of Allacor P, the first medical device derived from human umbilical cord extracellular matrix (ECM). Allacor P was awarded an A ...
Medical Device Network on MSN
StimLabs launches Allacor P for acute and chronic wound care
StimLabs has announced the launch of Allacor P, a human umbilical cord device designed for acute and chronic wound management ...
NewcelX Ltd. ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study ...
UK-based biotechnology company Engitix Ltd. has raised a further $25 million from billionaire Michael Platt to help develop its therapies for cancer and fibrosis.
TYBR Health has announced the first US clinical use of the collagen-based tissue protector, B3 GEL System, aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback